Details of the Drug

General Information of Drug (ID: DM8YU2F)

Drug Name
Mepenzolate
Synonyms
Cantil; Cantilaque; Cantilon; Cantril; Colibantil; Colopiril; Colum; Delevil; Eftoron; Gastropidil; Glycophenylate; Mepenzolon; Tralanta; Trancolon; Trokonil; Bromure de mepenzolate; Bromuro de mepenzolato; MEPENZOLATE BROMIDE; Mepenzolate Methylbromide; Mepenzolati bromidum; Mepenzolic acid; Mepenzolone Bromide; JB 340; Bromure de mepenzolate [INN-French]; Bromuro de mepenzolato [INN-Spanish]; Cantil (TN); Mepenzolati bromidum [INN-Latin]; Mepenzolic acid, bromine salt; Mepenzolate bromide (JP15/INN); Mepenzolate bromide [INN:BAN:JAN]; N-Methyl-3-piperidyl benzilate methobromide; N-Methyl-3-piperidyl benzilate methyl bromide; N-Methyl-3-piperidyldiphenylglycolate methobromide; N-methyl-3-piperidylbenzilate methyl bromide; Benzilic acid, 1-methyl-3-piperidyl ester methobromide; Benzilic acid, ester with 3-hydroxy-1,1-dimethylpiperidinium bromide; Piperidinium, 3-[(hydroxydiphenylacetyl)oxy]-1,1-dimethyl-, bromide; Piperidinium, 3-hydroxy-1,1-dimethyl-, benzilate (ester); Piperidinium, 3-hydroxy-1,1-dimethyl-, bromide, benzilate; Piperidinium, 3-((hydroxydiphenylacetyl)oxy)-1,1-dimethyl-(VAN); Piperidinium, 3-((hydroxydiphenylacetyl)oxy)-1,1-dimethyl-, bromide; (1,1-dimethylpiperidin-1-ium-3-yl) 2-hydroxy-2,2-diphenylacetate; (1,1-dimethylpiperidin-1-ium-3-yl) 2-hydroxy-2,2-diphenylacetate bromide; 1-Methyl-3-piperidyl benzilate methyl bromide; 1-Methyl-3-piperidyl benzilate methylbromide; 2-(1,1-dimethylpiperidin-1-ium-3-yl)oxy-2-oxo-1,1-diphenylethanolate; 2-[(1,1-dimethylpiperidinium-3-yl)oxy]-2-oxo-1,1-diphenylethanolate; 3-((Hydroxydiphenylacetyl)oxy)-1,1-dimethylpiperidinium bromide; 3-Hydroxy-1,1-dimethylpiperidinium bromide benzilate; 3-{[hydroxy(diphenyl)acetyl]oxy}-1,1-dimethylpiperidinium bromide
Indication
Disease Entry ICD 11 Status REF
Gastric ulcer DA60 Approved [1]
Gastrointestinal disease DE2Z Approved [2]
Peptic ulcer DA61 Approved [2]
Therapeutic Class
Parasympatholytics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 340.4
Logarithm of the Partition Coefficient (xlogp) 3.2
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
Chemical Identifiers
Formula
C21H26NO3+
IUPAC Name
(1,1-dimethylpiperidin-1-ium-3-yl) 2-hydroxy-2,2-diphenylacetate
Canonical SMILES
C[N+]1(CCCC(C1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O)C
InChI
InChI=1S/C21H26NO3/c1-22(2)15-9-14-19(16-22)25-20(23)21(24,17-10-5-3-6-11-17)18-12-7-4-8-13-18/h3-8,10-13,19,24H,9,14-16H2,1-2H3/q+1
InChIKey
GKNPSSNBBWDAGH-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4057
ChEBI ID
CHEBI:94411
CAS Number
25990-43-6
DrugBank ID
DB04843
TTD ID
D0FV3V
VARIDT ID
DR00973
ACDINA ID
D00396
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Muscarinic acetylcholine receptor M5 (CHRM5) TTH18TF ACM5_HUMAN Antagonist [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Mepenzolate (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Oliceridine DM6MDCF Moderate Additive CNS depression effects by the combination of Mepenzolate and Oliceridine. Acute pain [MG31] [4]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Mepenzolate and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [5]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Mepenzolate and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [5]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Mepenzolate and Cariprazine. Bipolar disorder [6A60] [6]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Mepenzolate and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [7]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Mepenzolate and Revefenacin. Chronic obstructive pulmonary disease [CA22] [7]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Mepenzolate and OPC-34712. Depression [6A70-6A7Z] [6]
Nebivolol DM7F1PA Moderate Additive CNS depression effects by the combination of Mepenzolate and Nebivolol. Hypertension [BA00-BA04] [8]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Mepenzolate and Belladonna. Infectious gastroenteritis/colitis [1A40] [6]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Mepenzolate and ITI-007. Insomnia [7A00-7A0Z] [6]
R0-93877 DMM4U9G Moderate Antagonize the effect of Mepenzolate when combined with R0-93877. Irritable bowel syndrome [DD91] [9]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Mepenzolate and Methylscopolamine. Peptic ulcer [DA61] [6]
Iloperidone DM6AUFY Moderate Additive anticholinergic effects by the combination of Mepenzolate and Iloperidone. Schizophrenia [6A20] [6]
Asenapine DMSQZE2 Moderate Additive anticholinergic effects by the combination of Mepenzolate and Asenapine. Schizophrenia [6A20] [6]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Mepenzolate and Acrivastine. Vasomotor/allergic rhinitis [CA08] [5]
⏷ Show the Full List of 15 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Hydrazine yellow E00409 164825 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Mepenzolate 25 mg tablet 25 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Mepenzolate FDA Label
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 010679.
3 Isolation of cholinergic active ingredients in aqueous extracts of Mareya micrantha using the longitudinal muscle of isolated guinea-pig ileum as a pharmacological activity marker. J Ethnopharmacol. 1995 Mar;45(3):215-22.
4 Product Information. Exalgo (hydromorphone). Covidien, Mansfield, MA.
5 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
6 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
7 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
8 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
9 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".